Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | NQO1 | P15559 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266171 | 0.86 | HTT (0.53) | HTTMAPTNQO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL19364256 | 0.83 | HTT (0.42) | HTTMAPTNQO1SLC5A2SMN1; SMN2 | |
| SCHEMBL12141758 | 0.82 | NNMT (0.41) | HTTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL24468432 | 0.79 | HTT (0.46) | HTTMAPTSLC5A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL45848 | 0.78 | TP53 (0.33) | SLC5A2ALDH1A1TP53POLB | |
| SCHEMBL4591932 | 0.77 | HTT (0.39) | HTTMAPTNQO1SLC5A2SMN1; SMN2 | |
| SCHEMBL18291293 | 0.77 | HTR1B (0.42) | ALDH1A1 | |
| SCHEMBL29761634 | 0.76 | HTT (0.46) | HTTMAPTNQO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13576998 | 0.76 | HTT (0.46) | HTTMAPTNQO1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26581934 | 0.75 | MAOB (0.42) | HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-7390810-B2 | Pyrazole-amine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241575-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | HTT 1087/4885MAPT 1236/4885NQO1 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.